MANCHESTER, UK -- RTI Health Solutions (RTI-HS) developed the National Institute for Health and Clinical Excellence (NICE) and National Center for Pharmacoeconomics (NCPE) submissions for denosumab (ProliaTM). Prolia is a prescription medication for prevention of osteoporotic fractures in postmenopausal women. Both the NICE and the NCPE have recommended denosumab within its licensed indication. The submission to the Scottish Medicines Consortium (SMC) is still being assessed.
In supporting these successful submissions, RTI-HS provided strategic input, prepared budget impact estimates, developed the full submission dossiers and prepared responses to requests from NICE and NCPE.
For more information contact Sorrel Wolowacz or call 44.(0)161.232.3400